Biotechnology Fund Financials
| RYBOX Fund | USD 68.96 0.15 0.22% |
Biotechnology |
Please note that you must use caution to infer results of funds future performance. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost.
Biotechnology Fund Fund Summary
Biotechnology Fund competes with Baron Health, Alger Health, The Hartford, Allianzgi Health, and Highland Longshort. Under normal circumstances, the fund invests substantially all of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.Specialization | Health, Large |
| Instrument | USA Mutual Fund View All |
| Exchange | NMFQS Exchange |
| Business Address | Rydex Series Funds |
| Mutual Fund Family | Rydex Funds |
| Mutual Fund Category | Health |
| Benchmark | Dow Jones Industrial |
| Phone | 800 820 0888 |
| Currency | USD - US Dollar |
Biotechnology Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Fund's current stock value. Our valuation model uses many indicators to compare Biotechnology Fund value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Fund competition to find correlations between indicators driving Biotechnology Fund's intrinsic value. More Info.Biotechnology Fund Class is rated below average in price to earning among similar funds. It is rated third largest fund in price to book among similar funds fabricating about 0.19 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Biotechnology Fund Class is roughly 5.22 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotechnology Fund's earnings, one of the primary drivers of an investment's value.Biotechnology Fund Class Systematic Risk
Biotechnology Fund's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biotechnology Fund volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Biotechnology Fund Class correlated with the market. If Beta is less than 0 Biotechnology Fund generally moves in the opposite direction as compared to the market. If Biotechnology Fund Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biotechnology Fund Class is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biotechnology Fund is generally in the same direction as the market. If Beta > 1 Biotechnology Fund moves generally in the same direction as, but more than the movement of the benchmark.
Biotechnology Fund December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biotechnology Fund help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biotechnology Fund Class. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biotechnology Fund Class based on widely used predictive technical indicators. In general, we focus on analyzing Biotechnology Mutual Fund price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biotechnology Fund's daily price indicators and compare them against related drivers.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 6.21 | |||
| Value At Risk | (1.75) | |||
| Potential Upside | 1.51 |
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Fund financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Fund security.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |